News

Hyphens Pharma officially launches WellAway, Singapore’s first HSA-registered e-pharmacy

Download as PDF

Press Release 

  • More than 100 clinics have signed up since the license was awarded in January 2021
  • Entered into collaboration with pharmaceutical group, Servier Singapore, to enable home delivery of prescribed medications

Singapore, 10 January 2022 – Hyphens Pharma International Limited (“Hyphens Pharma”, “凯帆药剂国际有限公司”, or the “Company”, and together with its subsidiaries, the “Group”), Singapore’s leading specialty pharmaceutical and consumer healthcare group, has officially launched its WellAway e-pharmacy (“WellAway”, or the “E-Pharmacy”) today.

WellAway is Singapore’s first Health Sciences Authority (“HSA”) registered e-pharmacy. It is a digital platform where patients can receive e-prescriptions from a qualified medical doctor and have the prescribed medicine delivered directly to them in a safe and secure manner.

As an e-pharmacy, WellAway follows very stringent HSA guidelines which include the safe supply and delivery of medication and the protection of patient data. Its supply chain ensures the quality and integrity of the medication delivered, with additional specialised handling for temperature sensitive medication. Patients will also receive medication counselling in the process. This sets the industry gold standard for end-to-end medication home delivery, in terms of both safety and efficiency for patients.

WellAway provides patients with convenience of access to pharmacy services and complement doctors in the practice of teleconsultation. This service is especially useful for patients that are aged, immobile, self-isolating, or just prefer to reduce their contact time outdoors, especially during the current time of the COVID-19 pandemic.

Since WellAway was awarded its e-pharmacy license by HSA in January 2021, more than 100 clinics have registered for a WellAway account. With this official launch of WellAway, we will be reaching out to all doctors to offer them this service.

With the help of digital technology, WellAway has the potential to enhance patients’ experience and compliance with medication, thus ultimately improving overall treatment outcome. Pharmaceutical group, Servier Singapore, has seen this potential and is working closely with WellAway to further explore these possibilities.

Mr Lim See Wah (“林世华”), Executive Chairman and CEO of Hyphens Pharma commented: “Healthcare digitalisation is a key trend that is amplified by COVID-19. With WellAway, we are able to contribute to this development. We are particularly excited that Servier Singapore sees the potential of WellAway and is actively collaborating with us to further develop our services. We believed that our close collaboration with doctors and the pharmaceutical industries will ultimately contribute to improved patient experience and outcome.”

Mr Florent De Kertanguy, General Manager of Servier Singapore added: “I believe that digitalisation is the future of the pharmaceutical industry and working with WellAway certainly allows us to better serve our patients’ needs in the new digital era.”

End.

 

About Hyphens Pharma International Limited

Hyphens Pharma International Limited and its subsidiaries (the “Group“) is Singapore’s leading specialty pharmaceutical and consumer healthcare group, leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in Singapore, Vietnam, Malaysia, Indonesia and the Philippines, and is supplemented by a marketing and distribution network covering 10 other markets – Bangladesh, Brunei, Cambodia, China, Hong Kong S.A.R., Macau S.A.R., Myanmar, Oman, South Korea and Sri Lanka.

Singapore is the Group’s regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based. The Group’s core business comprises the following segments: Specialty Pharma Principals, Proprietary Brands, and Medical Hypermart & Digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies.

For more information, please visit https://www.hyphensgroup.com 

Issued on behalf of Hyphens Pharma International Limited

For enquiries, please contact:
Ms Foo En Yun, Tel: (65) 6704 9284, Mob: (65) 8180 3641, Email: [email protected]
Mr Gerald Woon, Tel: (65) 6704 9268, Mob: (65) 9694 8364, Email: [email protected]

This media release has been reviewed by the Company’s sponsor, SAC Capital Private Limited (the “Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this media release, including the correctness of any of the statements or opinions made or reports contained in this media release.

The contact person for the Sponsor is Ms Lee Khai Yinn (Tel: (65) 6232 3210) at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542.